vs
Intapp, Inc.（INTA）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Intapp, Inc.的1.6倍（$219.9M vs $140.2M），Orthofix Medical Inc.净利率更高（-1.0% vs -4.2%，领先3.2%），Intapp, Inc.同比增速更快（15.7% vs 2.0%），Intapp, Inc.自由现金流更多（$22.2M vs $16.8M）
Intapp是一家全球云软件供应商，专注服务律所、会计师事务所、咨询机构、私募股权公司、投资银行等专业服务领域客户，提供客户生命周期管理、风险合规、运营流程自动化、财务绩效管理等相关解决方案，核心市场覆盖北美、欧洲及亚太地区。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
INTA vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$140.2M
营收增速更快
INTA
高出13.7%
2.0%
净利率更高
OFIX
高出3.2%
-4.2%
自由现金流更多
INTA
多$5.4M
$16.8M
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.2M | $219.9M |
| 净利润 | $-5.9M | $-2.2M |
| 毛利率 | 75.0% | 71.1% |
| 营业利润率 | -5.1% | 0.2% |
| 净利率 | -4.2% | -1.0% |
| 营收同比 | 15.7% | 2.0% |
| 净利润同比 | 41.9% | 92.4% |
| 每股收益（稀释后） | $-0.07 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INTAOFIX
| Q4 25 | $140.2M | $219.9M | ||
| Q3 25 | $139.0M | $205.6M | ||
| Q2 25 | — | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $215.7M | ||
| Q3 24 | — | $196.6M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $188.6M |
净利润INTAOFIX
| Q4 25 | $-5.9M | $-2.2M | ||
| Q3 25 | $-14.4M | $-22.8M | ||
| Q2 25 | — | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | — | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率INTAOFIX
| Q4 25 | 75.0% | 71.1% | ||
| Q3 25 | 74.7% | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率INTAOFIX
| Q4 25 | -5.1% | 0.2% | ||
| Q3 25 | -10.4% | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率INTAOFIX
| Q4 25 | -4.2% | -1.0% | ||
| Q3 25 | -10.3% | -11.1% | ||
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | — | -13.9% | ||
| Q2 24 | — | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）INTAOFIX
| Q4 25 | $-0.07 | $-0.05 | ||
| Q3 25 | $-0.18 | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $191.2M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $410.2M | $450.0M |
| 总资产 | $795.2M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INTAOFIX
| Q4 25 | $191.2M | $82.0M | ||
| Q3 25 | $273.4M | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务INTAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益INTAOFIX
| Q4 25 | $410.2M | $450.0M | ||
| Q3 25 | $486.4M | $442.5M | ||
| Q2 25 | — | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | — | $503.1M | ||
| Q3 24 | — | $525.9M | ||
| Q2 24 | — | $546.0M | ||
| Q1 24 | — | $570.3M |
总资产INTAOFIX
| Q4 25 | $795.2M | $850.6M | ||
| Q3 25 | $823.3M | $832.6M | ||
| Q2 25 | — | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | — | $893.3M | ||
| Q3 24 | — | $867.9M | ||
| Q2 24 | — | $882.0M | ||
| Q1 24 | — | $906.0M |
负债/权益比INTAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $22.2M | $16.8M |
| 自由现金流率自由现金流/营收 | 15.8% | 7.6% |
| 资本支出强度资本支出/营收 | 0.5% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流INTAOFIX
| Q4 25 | $22.9M | $27.7M | ||
| Q3 25 | $13.8M | $12.4M | ||
| Q2 25 | — | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | — | $9.0M | ||
| Q1 24 | — | $-18.6M |
自由现金流INTAOFIX
| Q4 25 | $22.2M | $16.8M | ||
| Q3 25 | $13.2M | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率INTAOFIX
| Q4 25 | 15.8% | 7.6% | ||
| Q3 25 | 9.5% | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度INTAOFIX
| Q4 25 | 0.5% | 4.9% | ||
| Q3 25 | 0.4% | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INTA
| Saa S | $102.5M | 73% |
| License | $25.4M | 18% |
| Professional Services | $12.3M | 9% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
